Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Rhea-AI Summary
Vivoryon Therapeutics (Euronext: VVY) announced management will attend and present at several medical and investor conferences in early 2026. Scheduled events include 1x1s around J.P. Morgan Healthcare Conference in San Francisco on Jan 12–14, 2026, the UBS European Healthcare Conference in London on Mar 3–4, 2026, and the World Congress of Nephrology (WCN) in Yokohama on Mar 28–31, 2026. The company focuses on small‑molecule therapies for inflammatory and fibrotic kidney diseases. For investor meetings contact: IR@vivoryon.com. A link to WCN is provided for conference details.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Market Pulse Summary
This announcement highlights Vivoryon’s planned presence at several investor and medical conferences in January and March 2026, signaling an active outreach effort to both the financial community and nephrology specialists. With no accompanying financial or clinical data in this release, investors would typically watch for subsequent updates tied to these meetings, such as trial readouts, partnership developments, or changes in strategic priorities, to better assess the impact on the company’s outlook.
Jargon Translator
AI-generated analysis. Not financial advice.
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences:
1x1s around J.P. Morgan Healthcare Conference
San Francisco, USA
Date: January 12-14, 2026
To meet the team contact: IR@vivoryon.com
UBS European Healthcare Conference
London, UK
Date: March 3-4, 2026
World Congress of Nephrology (WCN)
Yokohama, Japan
Date: March 28-31, 2026
Link to conference: https://www.theisn.org/wcn/
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
When will Vivoryon (VVY) hold 1x1 meetings around J.P. Morgan Healthcare Conference?
How can investors request a meeting with Vivoryon management at the January 2026 events (VVY)?
Will Vivoryon (VVY) present at the World Congress of Nephrology in 2026 and when?
What dates will Vivoryon (VVY) attend the UBS European Healthcare Conference in 2026?
What is Vivoryon's (VVY) clinical focus mentioned for the 2026 conferences?
